source
- Novartis to cut about 130 jobs in Switzerland as it reshapes biologics production in BaselNovartis announced it will eliminate roughly 130 positions in Switzerland as part of a reorganization of its biologics technical development and manufacturing footprint in Basel. The company plans…
- Novartis’ BTK inhibitor remibrutinib cuts MS relapse rates in Phase 3, setting up FDA filingNovartis reported that its BTK inhibitor remibrutinib, already approved for chronic spontaneous urticaria, lowered annualized relapse rates in two Phase 3 studies of relapsing multiple sclerosis wh…